Cannabis is having one of those moments again.
Headlines are flying. Group chats are buzzing. Stocks are moving. Politicians are lining up to take credit. After more than fifty years in Schedule I, cannabis is finally being acknowledged by the federal government as having medical value.
That alone is historic. It’s the U.S. government, at long last, admitting something millions of patients, growers, doctors and caregivers have known for decades.
But if you’ve been around this plant long enough, you also know how these moments tend to go.
Progress arrives carrying conditions. Relief comes stapled to new rules. And “recognition” often turns into regulation written by people who were never part of the culture they’re now managing.
So yes, Schedule III matters. And yes, it’s okay to feel cautiously optimistic. It’s also worth slowing down before we call this a win.
Before we get lost in speculation, it helps to understand what actually just happened. That’s where a new breakdown from VERDANT Strategies’ Hirsh Jain comes in.
In a video, Jain does something rare in cannabis policy conversations. He turns the volume down. No hype. No promises. Just a clear explanation of what rescheduling is, what it isn’t, and where the real implications begin and end.
What actually changed
On December 18, President Donald Trump signed an executive order directing the attorney general to complete the rulemaking process to move cannabis from Schedule I to Schedule III under the Controlled Substances Act.
- That does not mean cannabis is now legal federally. It isn’t.
- It does not mean interstate commerce opens up. It doesn’t.
- It does not mean banks and stock exchanges suddenly roll out the red carpet.
- It does not fix criminal justice issues or expunge criminal records. Even non-violent cannabis offenders would remain incarcerated under current federal law.
What it does mean is this: the federal government is formally acknowledging that cannabis has accepted medical use. That acknowledgment alone collapses the logic that has propped up prohibition since 1971.
Jain walks through how this process has been years in the making, built on scientific review, legal analysis and administrative hearings. It’s not a tweet. It’s not a vibe shift. It’s bureaucracy finally catching up to reality.
A key piece of that groundwork came through evidentiary hearings before a DEA administrative law judge, where expert testimony, cross-examination and findings on medical use, safety and abuse potential were formally entered into the record. That matters because federal courts tend to defer to agency decisions built on a strong administrative foundation. In other words, this isn’t just symbolic. It’s designed to hold up.
If the rule survives expected legal challenges, it would take effect shortly after being published in the Federal Register.
Here’s the full breakdown.
This moment also didn’t come out of nowhere. As Jain notes, rescheduling is deeply rooted in the medical cannabis movement that began decades ago at the state and local level, particularly in California. Long before Washington was willing to engage, patients, caregivers and doctors were already treating cannabis as medicine, often in defiance of federal policy. Over time, that reality made the Schedule I fiction harder and harder to defend.
Why operators are watching so closely
For growers and business owners, the headline everyone jumps to is taxes.
If cannabis is no longer classified as Schedule I or II, IRS code section 280E should no longer apply, though timing and scope will ultimately depend on IRS guidance and interpretation. That could dramatically change the math for an industry that has been punished, year after year, for operating legally.
That relief is real. But it’s not a reset button.
As Jain points out, many operators are carrying years of unresolved tax exposure. And history shows that when costs come down, prices often follow. Lower prices help legal operators compete with the illicit market, but they don’t automatically mean healthier margins or safer futures.
Rescheduling helps. It doesn’t rescue.
Research gets easier. Control gets closer.
Schedule III also lowers barriers to research. Universities and authorized institutions would face fewer obstacles than they did under Schedule I, which treated cannabis science like a crime scene.
It’s progress, but not a free pass. Researchers would still face DEA registration requirements, FDA oversight, sourcing limitations and funding constraints. Rescheduling makes research more possible. It does not make it simple.
But research pathways also shape power. Who gets funded. Who gets approved. Which forms of cannabis are studied, standardized and deemed legitimate.
When cannabis becomes “medicine” in the federal sense, it starts moving through systems that already exist. Systems dominated by pharmaceutical logic, insurance frameworks and regulatory comfort zones that rarely favor small players or whole-plant complexity.
That doesn’t make rescheduling bad. It makes it consequential.
The question underneath the celebration
High Times isn’t focused on victory laps. It’s focused on who takes control when policy shifts.
So it’s worth asking the questions that tend to come after the applause fades.
What’s also unusual about this moment is the politics around it. While the rescheduling process began under President Biden, it was President Trump who directed its completion. In a deeply polarized era, that kind of bipartisan acknowledgment is rare. It may give rescheduling durability. It also complicates the narrative, especially when some of the same lawmakers who oppose broader cannabis reform are now positioned as gatekeepers of what comes next.
Jain also flags that congressional obstacles remain, including House Speaker Mike Johnson and Senate Majority Leader John Thune, both of whom have been unfriendly to cannabis reform. That’s a reminder that rescheduling is not the end of political friction. It’s a new shape of it.
- Does rescheduling help small growers survive, or does it accelerate consolidation?
- Does medical legitimacy expand access, or quietly funnel cannabis into narrower, more corporate channels?
- Does federal recognition protect the culture, or domesticate it?
And maybe the hardest one: Could Schedule III, done wrong, end up being more restrictive in practice than Schedule I ever was?
None of this is inevitable. But none of it is imaginary either.
Beyond the U.S., the implications ripple outward. For much of the last century, American drug policy shaped the global war on drugs through treaties, diplomacy and pressure. A formal acknowledgment of cannabis as medicine at the federal level could give other countries political space to reform their own laws, particularly across Latin America and Europe. Rescheduling doesn’t end prohibition worldwide, but it may loosen its grip.
A reset, not a finish line
Jain is careful not to oversell what’s happening. Rescheduling is a structural reset. Not legalization. Not justice. Not freedom.
For operators, it’s a moment to clean up, get disciplined and prepare for a market that may become more rational and more competitive at the same time.
For the culture, it’s a reminder to stay awake.
Cannabis didn’t survive prohibition just to be handed over quietly to the same institutions that once said it had no value at all.
Schedule III opens a door. Who walks through it, and who gets locked out, is still very much up for grabs.
High Times will be watching closely.
